Glenmark Pharmaceuticals Inc., USA launched Vancomycin Hydrochloride for Injection USP in 500 mg/vial and 1 g/vial strengths.
The product is bioequivalent to Fresenius Kabi's reference drug and addresses a market with annual sales of approximately $37.9 million.
The launch strengthens Glenmark's injectable portfolio and supports its commitment to expanding access to affordable medicines in the US.